Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

About this episode

Shun Lu discusses the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy for advanced squamous non-small-cell lung cancer.

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thela...

People in this episode

Host: Ben Abbott

Guest: Shun Lu

Topics covered

• cancer treatment
• clinical trials
• bispecific antibodies
• lung cancer
• medical research

Keywords

• HARMONi-6
• ivonescimab
• squamous NSCLC
• ESMO 2025
• clinical trial

Mentioned in this episode

Organizations: The Lancet, ESMO

Products: ivonescimab

Places: advanced squamous non-small-cell lung cancer

More episodes of The Lancet in conversation with

• Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology · May 31, 2026 · 33 min
• Paul Spiegel: rethinking the humanitarian response to conflict and forced displacement · May 19, 2026 · 32 min
• Can semaglutide be used to treat alcohol use disorder? · May 2, 2026 · 32 min
• Louise Chappell and Na’ama Carlin on Personal Cancer Stories · February 3, 2026 · 31 min
• Susannah Stanway on the London Global Cancer Week · December 19, 2025 · 24 min
• Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health · December 9, 2025 · 1h 1m